Search

Your search keyword '"Jacquelinet C"' showing total 327 results
Start Over Author "Jacquelinet C"
327 results on '"Jacquelinet C"'

4. Public Health Decision Support

Author

Jacquelinet, C., Belhadj, I., Bayer, F., Sauleau, E., Lévy, P., Chaudet, H., Venot, Alain, editor, Burgun, Anita, editor, and Quantin, Catherine, editor

Published
2014
Full Text
View/download PDF

8. Evolution du profil cognitive des patients ayant une maladie rénale chronique : étude longitudinale de la cohorte CKD REIN

Author

Levassort, H., primary, Pépin, M., additional, Boucquemont, J., additional, Lambert, O., additional, Alencar De Pinho, N., additional, Turinici, M., additional, Helmer, C., additional, Metzger, M., additional, Teillet, L., additional, Frimat, L., additional, Combe, C., additional, Fouque, D., additional, Laville, M., additional, Ayav, C., additional, and Jacquelinet, C., additional

Published
2022
Full Text
View/download PDF

19. Public Health Decision Support

Author

Jacquelinet, C., primary, Belhadj, I., additional, Bayer, F., additional, Sauleau, E., additional, Lévy, P., additional, and Chaudet, H., additional

Published
2013
Full Text
View/download PDF

29. Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort

Author

Laville, S. M., Metzger, M., Stengel, B., Jacquelinet, C., Combe, C., Fouque, Denis, Laville, M., Frimat, L., Ayav, C., Speyer, E., Robinson, B. M., Massy, Z. A., Liabeuf, S., Chronic Kidney Dis Renal, Epidemiol, Information Network, C. K. D. Rein Stud, Université de Picardie Jules Verne (UPJV), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Agence de la biomédecine [Saint-Denis la Plaine], Service de Néphrologie-Transplantation-Dialyse, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Service d'Epidémiologie et Evaluations Cliniques [CHRU Nancy] (Pôle S2R), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Réseau Lorrain de prise en charge de l’insuffisance rénale chronique : Réseau NEPHROLOR (Nephrolor), Service Néphrologie/Dialyse [AP-HP Ambroise-Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Centre de Recherche Clinique, CHU Amiens-Picardie, CKD REIN, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Néphrologie [Ambroise Paré], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Service de Néphrologie Transplantation, Dialyse et Aphérèse [CHU Bordeaux], CHU Bordeaux [Bordeaux], INSERM U1026 (INSERM, U1026), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Université de Lyon-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National de la Recherche Agronomique (INRA), Service de Néphrologie [CHRU Nancy], Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Arbor Research Collaborative for Health, Mécanismes physiopathologiques et conséquences des calcifications vasculaires - UR UPJV 7517 (MP3CV), Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), DIPI (DIPI), ENISE, Mécanismes physiologiques et conséquences des calcifications cardiovasculaires: rôle des remodelages cardiovasculaires et osseux, and Université de Picardie Jules Verne (UPJV)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
pharmacoepidemiology, adjustment, [SDV]Life Sciences [q-bio], cockcroft-gault, prescribing, urologic and male genital diseases, female genital diseases and pregnancy complications, information, medications, equations, residents, community, epidemiology, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, guidelines, Pharmacology & Pharmacy, drug utilization, ComputingMilieux_MISCELLANEOUS, chronic kidney disease
Abstract

International audience; Aims Drug prescription is difficult to manage in patients with chronic kidney disease (CKD). We assessed the prevalence and determinants of inappropriate drug prescriptions (whether contraindications or inappropriately high doses) with regard to kidney function in patients with CKD under nephrology care. We also assessed the impact of the equation used to estimate GFR on the prevalence estimates. Methods Results The CKD-REIN cohort includes 3033 outpatients with CKD (eGFR between 15 and 60 ml min(-1) 1.73 m(-2)). We examined the daily doses of pharmacological agents prescribed at study entry. Inappropriate prescription was defined as the reported prescription of either a contraindicated drug or an indicated drug at an inappropriately high dose level with regard to the patient's GFR, as estimated with the CKD-EPI equation, the de-indexed CKD-EPI equation, or the Cockcroft-Gault (CG) equation. Multivariate logistic regression was used to assess the determinants of inappropriate prescription risk. At baseline, patients' median [interquartile range] number of drugs prescribed per patient was 8 [5-10]. Half of the patients had been prescribed at least one inappropriate drug. Anti-gout, cardiovascular agents and antidiabetic agents accounted for most of the inappropriate prescriptions. The percentage of inappropriate prescriptions varied from one GFR equation to another: 52% when using the CKD-EPI equation, 47% when using the de-indexed CKD-EPI equation and 41% with the CG equation. A multiple logistic regression analysis showed significantly higher odds ratios [95% confidence interval] for inappropriate prescriptions in male patients (1.28 [1.07; 1.53]), patients with diabetes (1.34 [1.06; 1.70]), those with a high BMI (1.58 [1.25; 1.99]), and those with a low GFR (10.2 [6.02; 17.3]). The risk of having at least one inappropriate prescription increased with the number of drugs per patient (P for trend \textless 0.0001) and therefore the odds ratio was 5.88 [4.17; 8.28] for those who received at least 11 prescribed medications compared to those who received fewer than 5. Conclusion Appendix Our results emphasize the complexity of drug management for CKD patients, for whom inappropriate prescription appears to be common.

Published
2018

35. The prognostic value of plasma viremia in HIV-infected patients under AZT treatment: a two-year follow-up study

Author

Ruffault, A., Michelet, C., Jacquelinet, C., Guist'hau, O., Genetet, N., Bariou, C., Colimon, R., and Cartier, F.

Subjects
HIV infection -- Development and progression, Zidovudine -- Health aspects, HIV (Viruses) -- Measurement, Health
Abstract

Measurements of HIV particles in blood plasma may correlate with disease progression in HIV-infected people who are being treated with AZT. Researchers obtained several measurements of HIV particles in plasma from 28 HIV-infected patients who were receiving AZT therapy. Patients were followed up for an average of 21 months. Although AZT lowered HIV plasma levels, the reduction did not last in 13 (46%) of the 28 patients who experienced progression of their HIV disease. The 15 patients whose disease did not progress experienced stable levels of HIV in plasma after the decrease. An increase of HIV in plasma may happen before a decrease in CD4 cell counts is seen. HIV patients receiving AZT whose disease progresses may need to receive other therapies to halt this progression.

Published
1995

Catalog

Books, media, physical & digital resources
See catalog results